By Drug Target Review –
Scientists have developed an organ-on-a-chip platform that replicates age-related immune decline, offering a long-missing tool for testing cancer vaccines in older adults.
Researchers at the Terasaki Institute have announced a pioneering organ-on-a-chip platform capable of replicating age-dependent immune responses, offering an important tool for assessing how cancer vaccines perform in older adults. The innovation, developed in the laboratory of Dr Vadim Jucaud, aims to fill a longstanding gap in preclinical testing, where the effects of ageing on the immune system are frequently overlooked despite their importance.
